{"database": "lobbying", "table": "lobbying_activities", "rows": [[907544, "3f5f44a1-9b61-4e99-9387-6e72d6db51ac", "Q1", "HOLLAND & KNIGHT LLP", 18466, "SHIRE PHARMACEUTICALS, INC", 2010, "first_quarter", "MMM", "Worked to keep provisions regarding biosimilar approval pathway in HR 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Reconciliation Act of 2010; Coverage of Elaprase in state Medicaid Plan.", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2010-03-29T14:35:26.860000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["907544"], "units": {}, "query_ms": 0.3208150155842304, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}